Portfolio
Formerly as Medivate Partners, Forward has invested in unique, disruptive biotech/healthcare companies with trans-pacific business reach. Mr. Paul Kim, CEO & Managing Partner, continues to lead the Forward team since when he first founded Medivate.
Under Mr. Kim’s leadership, Forward/Medivate has built a reputation & track record as the first private equity firm in Korea with expertise in cross-border/healthcare industry, focused on US/Asia region.
Portfolio
EXITED
COGNATE BIOSERVICES
Cognate BioServices is the one of the leading contract development and manufacturing organization (CDMO) for the commercialization of cell and gene therapy products. Cognate is the premier, commercial-ready CDMO in the industry with vast experience and expertise and provides all of the logistics and commercial readiness services to the biotech/pharma clients engaged in large late-phase clinical trials.
- February 2021
- Acquired by Charles River
GENOPIS, INC.
Genopis was established in 2018 by the joint venture between Forward Equity Partners (Medivate Partners) and KOSDAQ-listed gene therapy company, Helixmith (formerly ViroMed). Genopis is a contract development and manufacturing organization (CDMO) with commercial cGMP manufacturing capabilities of plasmid DNA.
- March 2021
- Acquired by WACKER Group
WCCT GLOBAL, INC.
WCCT Global, Inc., an early stage clinical research organization,
located in Southern California, was founded in 1998 and has conducted over 600 Phase I studies – an area it specializes in – out of over 1,000 Phase I-IV studies the company has conducted.
Canadian CRO Altasciences buy out WCCT Global, the company was then acquired itself by Novo Holdings.
- February 2021
- Acquired by Altasciences (Novo Holdings)
SILLAJEN
SillaJen, Inc. is a public (KOSDAQ-listed) biotechnology company focused on engineering and developing best-in-class oncolytic virus immunotherapeutics. SillaJen’s US affiliate, SillaJen Biotherapeutics, Inc., manages Clinical Operations, R&D, regulatory affairs and manufacturing capabilities. SillaJen Biotherapeutics is located in San Francisco, California.
- December 2017
- Exited on public market
Portfolio
Current
CHA Vaccine Institute
CHA Vaccine Institute is a research oriented biotechnology company. They research and develop a broad range of vaccine products targeting infectious disease as well as chronic disease. The core technology includes proprietary vaccine adjuvant L-pampo, recombinant antigen development platform.
- Homepage
- Invested on September 2024
RIVA THERAPEUTICS
Riva Therapeutics is a precision oncology company focused on creating transformative medicines for cancer patients. Riva is developing a new generation of small molecule therapeutics by leveraging deep knowledge of genomic dependencies to selectively target essential tumor cell processes beyond DNA damage repair. Riva's precision lethal therapies have the potential to provide profound clinical activity, be well-tolerated, and substantially improve patient lives. Research Allinance evolved from the Novo Broad Greenhouse, a joint initiative between Novo Ventures and the Broad Institute of MIT and Harvard.
- Homepage
- Invested on June 2023
GENOSCO
Genosco is a biotechnology company established in 2008 in Boston, USA, specializing in the development of protein kinase inhibitors for drug discovery. The company utilizes its proprietary G-SMART™ platform to identify various drug candidates. Genosco gained significant attention for developing Lazertinib, a treatment for non-small cell lung cancer. In 2015, Lazertinib was licensed to Yuhan Corporation and later sublicensed to Janssen in 2018. As of August 2024, the combination therapy of Lazertinib and Amivantamab received approval from the U.S. Food and Drug Administration (FDA) as a first-line treatment for non-small cell lung cancer.
- Homepage
- Invested on May 2023
CMG Pharmaceutical
CMG Pharmaceutical Co., Ltd is a Korea-based company specialized in the manufacture and distribute pharmaceutical products. Currently, the company is planning to expand its business to cell and gene therapy. For the purpose, the company decided to invest about 11M USD to Matica Biotechnology in 2023.
Matica Biotechnology: As a cell and gene therapy CDMO, they have a brand-new purpose-built GMP facility in Texas and are collaborating with two research partners: Sartorius and Texas A&M' University for Innovation in Advanced Development and Manufacturing. (website: https://www.maticabio.com)
- Homepage (CMG)
- Homepage (MATICA)
- Invested on March 2023
SCAI THERAPEUTICS
SCAI Therapeutics is a Korean biotech company developing novel proprietary drug delivery platform technology, MOASIS. MOASIS employs innovative formulation technologies aiming better drug delivery and bioavailability based on solubility enhancement of insoluble substances. This innovative drug delivery platform technology can be harnessed to show enhanced bioavailability, therapeutic efficacy, applicability, and safety with reduced toxicity, environmental hazard, and side-effects.
- Homepage
- Invested on July 2021
PARTNERS work with US
Our Co-GP Partners
We aim to invest in collaboration with various partners.
PARTNERS work with US
Our SyndicatePartners
Connect domestic investors with investment opportunities in the United States, where the healthcare industry is among the most developed.
Paul H. KIM, CEO & Managing Director